This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

J. B. Montoro, PhD; J. Oliveras, PharmD; C. Altisent, MD; I. Ruiz, PhD
Hospital Vall d'Hebron Barcelona, Spain

JAMA. 1997;277(1):20.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Dr O'Brien and colleagues¹ determined the influence of human immunodeficiency virus type 1 (HIV-1) RNA levels on the long-term incidence of the acquired immunodeficiency syndrome (AIDS) and survival in patients with hemophilia and HIV-1 infection. Levels of HIV-1 RNA strongly predicted time to development of AIDS. They found no association between HIV-1 RNA levels and the dose of non-heat-treated factor concentrate. Recent epidemiologic studies have found that the use of lower doses of factor concentrates was associated with an increased risk of progression to AIDS and mortality in patients with hemophilia.^2,3 This fact should justify the inclusion of the dose in the Cox proportional hazard models. Moreover, examining the data shown by O'Brien et al in their Table 1 using a test for linear trend rather than the Mantel-Haenszel ² test used by the authors, the P value for the comparison between RNA level . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?